Pharmaceutical regulatory data, drug approvals & compliance tracking
Home › Drug Approvals › 2026
This page provides comprehensive data and analytics for 2026 drug approvals. Our database is updated regularly to ensure accuracy and relevance. Our methodology combines automated data collection with expert curation to ensure high-quality, reliable information. Each data point is verified against multiple sources before publication.
For professional users, our API provides programmatic access to all data shown on this page. Rate limits apply based on your subscription tier. Contact us for enterprise pricing. Comparing these figures with historical averages reveals interesting patterns. The current period shows notable deviations from long-term trends in several categories, warranting closer examination.
This page is part of the FDA News data platform, which offers comprehensive coverage across related categories. Navigate using the links above to explore other sections.
| Drug | Type | Indication | Company | Date |
|---|---|---|---|---|
| Durvaxolimab | BLA | Lung cancer | PharmaCo Alpha | Apr 2026 |
| Retinoplast | NDA | Macular degeneration | OphthaCo | Mar 2026 |
| Cardioven | NDA | Heart failure | CardioLabs | Feb 2026 |
| Neurostim-X | BLA | Multiple sclerosis | NeuroPharma | Jan 2026 |
| Immunoguard | BLA | Rheumatoid arthritis | BioTech Zeta | Jan 2026 |
Data updated continuously. Last refresh: May 11, 2026 14:30 UTC.
